The recent surge in influenza cases across America is not just another seasonal occurrence; it’s an alarm bell signaling deeper issues within our healthcare system. Two seemingly unrelated events this week — the spike in flu cases and major pharmaceutical companies reporting record profits from vaccine sales — have Eagles asking questions.

While mainstream media reports the increase in deaths as a natural progression of flu seasons, Eagle Eye sees a pattern. The timing of the surge is noteworthy: right before critical elections where healthcare policy will play a significant role. Is this merely coincidence or something more sinister?

The Obama-era public health policies have been criticized for focusing on international health initiatives while neglecting domestic preparedness. As we face another severe flu season, it’s imperative to reevaluate these decisions.

Follow the money trail: pharmaceutical giants are among those who stand to benefit from a widespread illness, driving up demand and thus profits. This raises questions about their influence on public health policies and messaging around disease prevention.

This isn’t the first time we’ve seen patterns like this emerge. In 2018, during another severe flu season, similar spikes in pharmaceutical earnings were observed. Coincidence? Or is there a coordinated effort to control the narrative?

Public health officials under previous Democrat administrations have faced criticism for prioritizing global initiatives over domestic needs. Could this be part of an ongoing trend aimed at weakening public trust in local healthcare systems and redirecting funds away from citizens?

The current flu season’s severity is unprecedented, raising doubts about the effectiveness of existing policies. Eagles should investigate further: who benefits when Americans are sick? And why now?

It’s time to connect the dots between rising pharmaceutical profits and declining public health outcomes. This isn’t just a seasonal event; it could be part of a larger strategy.